Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study
Open Access
- 28 October 2008
- journal article
- conference paper
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 66 (5), 695-705
- https://doi.org/10.1111/j.1365-2125.2008.03261.x
Abstract
AIMS Recent studies have suggested a possible association between maternal use of selective serotonin reuptake inhibitors (SSRIs) in early pregnancy and cardiovascular anomalies. The aim of the present study was to evaluate the teratogenic risk of paroxetine and fluoxetine. METHODS This multicentre, prospective, controlled study evaluated the rate of major congenital anomalies after first-trimester gestational exposure to paroxetine, fluoxetine or nonteratogens. RESULTS We followed up 410 paroxetine, 314 fluoxetine first-trimester exposed pregnancies and 1467 controls. After exclusion of genetic and cytogenetic anomalies, there was a higher rate of major anomalies in the SSRI groups compared with the controls [paroxetine 18/348 (5.2%), fluoxetine 12/253 (4.7%) and controls 34/1359 (2.5%)]. The main risk applied to cardiovascular anomalies [paroxetine 7/348 (2.0%), crude odds ratio (OR) 3.47, 95% confidence interval (CI) 1.13, 10.58; fluoxetine 7/253 (2.8%), crude OR, 4.81 95% CI 1.56, 14.71; and controls 8/1359 (0.6%)]. On logistic regression analysis only cigarette smoking of >= 10 cigarettes day(-1) and fluoxetine exposure were significant variables for cardiovascular anomalies. The adjusted ORs for paroxetine and fluoxetine were 2.66 (95% CI 0.80, 8.90) and 4.47 (95% CI 1.31, 15.27), respectively. CONCLUSION This study suggests a possible association between cardiovascular anomalies and first-trimester exposure to fluoxetine.Keywords
This publication has 57 references indexed in Scilit:
- Evaluation of the Risk of Congenital Cardiovascular Defects Associated With Use of Paroxetine During PregnancyAmerican Journal of Psychiatry, 2008
- Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population‐based health dataBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2008
- Maternal use of selective serotonin re‐uptake inhibitors in early pregnancy and infant congenital malformationsBirth Defects Research Part A: Clinical and Molecular Teratology, 2007
- Prenatal Depression, Prenatal Anxiety, and Spontaneous Preterm Birth: A Prospective Cohort Study Among Women With Early and Regular CarePsychosomatic Medicine, 2006
- Post-marketing surveillance system for drugs in pregnancy—15 years experience of ENTISReproductive Toxicology, 2005
- Neonatal paroxetine withdrawal syndromeArchives of Disease in Childhood: Fetal & Neonatal, 2001
- Discontinuation Symptoms After Treatment With Serotonin Reuptake InhibitorsThe Journal of Clinical Psychiatry, 1997
- Developmental Toxicology Studies of Fluoxetine Hydrochloride Administered Orally to Rats and RabbitsFundamental and Applied Toxicology, 1994
- The reproductive toxicology of paroxetineActa Psychiatrica Scandinavica, 1989
- Prospective study of postpartum depression: Prevalence, course, and predictive factors.Journal of Abnormal Psychology, 1984